Contraline News
All posts

November 18, 2020

Male Contraceptive Initiative Invests $1 Millionin Contraline to Conduct Clinical Trial on ADAM™

Durham, NC and Charlottesville, VA Male Contraceptive Initiative MCI, a 501c3 non-profit, has partnered with the medical device company Contraline, Inc. to provide a 1 million Program Related Investment PRI to support a first-in-human clinical trial for the companys novel vas-occlusive contraceptive device, ADAM. This is the first PRI from Male Contraceptive Initiative and is representative of the organizations continued evolution. We are very excited about adding program related investments to our portfolio as a means of accelerating male contraceptive product development through a team science approach. Returns on these investments will go directly back into supporting research efforts to continue driving the field of non-hormonal male contraception forward, said MCI Executive Director Heather Vahdat. Contraline is a particularly exciting investment opportunity as they are the first US-based company to bring a novel non-hormonal male contraceptive to the clinical stage it shows that we are moving closer and closer to realizing a more robust portfolio of contraceptive options that includes more methods for men, Ms. Vahdat added. Contraline has developed ADAM, the worlds first injectable hydrogel designed to provide long-lasting barrier contraception for men. ADAM is designed to be inserted into the vas deferens through a quick and minimally invasive outpatient procedure using local anesthesia, where the hydrogel blocks the flow of sperm without affecting sensation or ejaculation. ADAM may be the first set-and-forget male contraceptive method, similar to intrauterine devices IUDs for women. MCIs investment in Contraline will be used to establish proof-of-concept of safety and feasibility of the ADAM device and procedure through a human clinical trial. This is an important first step prior to conducting a larger efficacy study required for gaining regulatory approval and widespread consumer access to the procedure. We have been excited about Contralines technology since 2018, when we provided them with a grant to validate their benchtop and preclinical studies. Given the success of their science to date, we are pleased to expand our collaboration as Contraline continues advancing their male contraceptive towards the clinic, said MCI Research Director Dr. Logan Nickels. We are grateful to MCI for their dedication to supporting innovation in male contraception and for recognizing the transformative potential of ADAM, said Kevin Eisenfrats, Contraline co-founder and chief executive officer. At Contraline, we are dedicated to developing new options for men who desire to take control of their fertility and we look forward to having our lead product, ADAM, enter the clinic soon. With over 5 million invested in product development, MCI seeks to advance male contraceptive research projects to market in order to achieve its organizational vision of Reproductive Autonomy for All. MCIs mission is, To empower men, and couples, to fully contribute to family planning goals by providing them the resources they need for reproductive autonomy. -------------------------------------------------- About Male Contraceptive Initiative Male Contraceptive Initiatives vision is Reproduction Autonomy for All, and works to accomplish this by bringing new male contraceptives to market. The non-profit accomplishes this through direct funding, technical support, research, and advocacy. They believe that couples deserve options and that they offer the biggest potential impact by focusing on male contraceptives. Its time men are given more opportunities to contribute toward family planning. About Contraline Contraline is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception. The company is developing ADAMTM, a non-hormonal male contraceptive that uses proprietary advancements in hydrogel technology for occlusion of the vas deferens. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia. To learn more, visit httpwww.contraline.com.

October 26, 2020

Virginia Catalyst Awards Contraline$600,000 for Clinical Translation

RICHMOND, VA October 26, 2020 The Virginia Catalyst, formerly known as the Virginia Biosciences Health Research Corporation VBHRC, today announced that it has awarded 2.1 million in grants to three life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded as Round 11 of Virginia Catalysts ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet needs for improving human health, and that can create high-paying jobs in the Commonwealth. The life sciences industry has been a catalyst for economic growth during the pandemic and is poised to accelerate Virginias recovery in a post COVID world, said Mike Grisham, CEO, Virginia Catalyst.Through programs like these grant initiatives, Virginia Catalyst and the Commonwealth of Virginia are investing in the future by driving additional capital and business opportunity through the life sciences. The funding we provide for these innovative programs helps generate significant outside capital and interest in Virginia. We are proud to announce the awardees for our eleventh round of funding as we help to finance the commercialization of Virginias innovations and investment in research infrastructure tools to facilitate bioscience research.Contraline is one of three companies to have been selected in this years round of funding. Contralines project, Clinical Translation of a Male Contraceptive Procedure will involve collaborating with UVA and VCU to prepare the companys lead product ADAM for use in humans.Nearly half of all pregnancies in the United States each year are unintended, with three-fourths of couples relying on the female partner for birth control. Currently, mens options are limited to condoms and vasectomy, creating a substantial opportunity for a novel male contraceptive to contribute to family planning and improved quality of life. Contraline, a spin-out from UVA, is a medical device company developing ADAM, the worlds first injectable hydrogel designed to provide long-lasting barrier contraception for men. The hydrogel is inserted into the vas deferens through a quick outpatient procedure, which has been shown to be safe and effective in large animal studies. The Virginia Catalyst grant will support our translational research collaborating with UVA and VCU urology departments to ready our male contraceptive ADAM for a first-in-human clinical trial in 2021. This will be the first clinical trial conducted on a non-hormonal male contraceptive device in over 20 years and we are excited to partner with Virginia Catalyst to enable it. - Kevin Eisenfrats, Co-Founder and Chief Executive Officer, Contraline, Inc.

September 30, 2020

Dr. Greg Groverto Present at Annual PODD Conference

CHARLOTTESVILLE, VA -- On October 9th, 2020, Dr. Greg Grover, Chief Technology Officer of Contraline, Inc., will present at the annual Partnership Opportunities in Drug Delivery PODD Conference. His talk titled, The Future of Male Contraception, is part of the Soapbox Sessions sponsored by Pfizer, which features presentations on cutting edge technologies and inventions. Dr. Grover will highlight Contralines key advancements in hydrogel technology as well as an update on Adam, a long-lasting and reversible contraceptive for men. For more information about the PODD Conference, please visit httpstheconferenceforum.orgconferencespartners-in-drug-deliveryoverviewhttpstheconferenceforum.orgconferencespartners-in-drug-deliveryoverview

January 24, 2019

Male Contraceptive InitiativeAwards Grant to Contraline

Charlottesville, VA Male Contraceptive Initiative MCI, a private non-profit foundation, announced the award of a 200,000 grant to the medical device company Contraline, Inc. for the development of a novel vas-occlusive contraceptive device. Contraline has invented a proprietary hydrogel that is implanted into the vas deferens through a minimally invasive, outpatient procedure. The hydrogel works by blocking sperm from traveling through the vas deferens. Similar to intrauterine devices IUDs for women, Contralines contraceptive is designed to last for years and be reversible. MCIs funding will be used by Contraline to refine the implantation procedure in preparation for filing with the FDA and initiating clinical trials.Vas-occlusion is a promising non-hormonal male contraceptive approach that has been attempted for decades, yet no product has been realized. Contraline has taken a new multidisciplinary approach towards solving this problem. Our team has developed a vas-occlusive hydrogel that is easily injectable, safe, and long-lasting. The key innovation is that we designed the hydrogel specifically for the vas environment and the occlusion of sperm. We are constantly improving the product and procedure with a focus on clinical translation and patient satisfaction, said Kevin Eisenfrats, Co-Founder and CEO of Contraline. We are honored that MCI has chosen to partner with Contraline to bring the first long-lasting, non-hormonal, and reversible male contraceptive to market.Bringing a non-hormonal, reversible method of male contraception to market is MCIs mission and were extremely excited about the work that Contraline is doing in the vas-occlusive space, adds MCI Executive Director Heather Vahdat. We believe that these methods have the potential to change the contraceptive landscape and we look forward to collaborating with the Contraline team in making this a reality.

April 22, 2018

Contraline CEO, Kevin Eisenfrats, to Present at the 43rd American Society of Andrology Conference

April 22, 2018 Charlottesville, Virginia Kevin Eisenfrats, Co-Founder and CEO of Contraline, Inc., will be sharing the history, current-state-of-the-art, and innovation in vas-occlusive medical devices in a featured talk at the American Society of Andrology 43rd Annual Conference in Portland, Oregon. His talk, titled The Past, Present, and Future of Vas-Occlusive Medical Devices, will be part of the symposium on male contraception on April 24th. The commercialization potential of methods to occlude the vas deferens have promise to be the first long-lasting, non-hormonal, and reversible male contraceptive approach. With about half of all pregnancies unplanned, and the burden of birth control mostly shouldered by women, there is a huge need for effective male contraception, said Kevin Eisenfrats. Contraline is dedicated to developing a long-acting, reversible contraceptive LARC for men and we are honored to be included among other leading researchers pursuing male contraceptive approaches.Other speakers in the symposium include Dr. Daniel Johnston, Chief of the NIH Contraception Research Branch Dr. Stephanie Page from the University of Washington and Dr. Michael ORand from the University of North Carolina. The symposium will highlight funding available for male contraceptive research, as well as provide updates on various hormonal and non-hormonal male contraceptive drugs in development. About ContralineContraline is a medical device company developing novel hydrogels for reproductive and contraceptive applications. The Company is focused on providing couples with new options for male contraception with a long-acting, non-hormonal, and reversible device. Contralines first product in development is Adam, which applies cutting-edge hydrogel technology to physically block sperm within the male reproductive tract.

September 27, 2017

Acceptability of a Long-LastingReversible Male Contraceptive

This article, written by Contralines CEO Kevin Eisenfrats, was originally postedhttpsctiexchange.orgfinding-acceptable-long-acting-reversible-male-contraceptive to FHI360s Contraceptive Technology Innovation CTI Exchange as part of their guest-author blog series. Almost every month or so, an article is published that reads New male contraceptive is on the horizon MIT Tech Reviewhttpswww.technologyreview.coms608333the-tech-world-is-convinced-2021-is-going-to-be-the-best-year-ever has even gone so far as to say that male birth control might be one of the most interesting technologies to be released in 2021, alongside electric vehicles, virtual reality, and lab-grown chickens. Judging by the headlines, youd think that men are as excited to try a male contraceptive as they are to drive the Tesla Model 3.Are they excited We know for sure that men are NOT excited about existing methods. Condoms have a dissatisfaction rate of 57 and the number of vasectomies performed in the U.S. has stagnated at 500,000 per year. We also know that men ARE interested in controlling their fertility over the long-term. In a 2005 studyhttpsacademic.oup.comhumreparticle202549603220 of 9,000 men across nine countries, 55 of the respondents reported being willing or very willing to use a new method of male contraception. That ranged from 28.5 in Indonesia to 71.4 in Spain. The most appealing frequency for taking the contraceptive Once per year so it seems interest among men in a long-acting contraceptive option is real.The next question then is whether a hormonal method would be acceptable. In a recent clinical trialhttpsacademic.oup.comjcemarticle-lookupdoi10.1210jc.2016-2141 sponsored by the World Health Organization, men were injected with a hormonal contraceptive under development that would provide contraception for up to a year. The study regimen was not easy each man received an injection of a testosterone and progestin derivative into his gluteus every eight weeks, and was required to come back for semen analysis and physical check-ups every two weeks. The contraceptive was found to be 96 effective a very good rating, but not as effective as vasectomy, the Pill, IUDs, or implants. However, a high number of adverse effects 1,491 to be exact, including acne, increased libido, depression, and mood disorders, were noted. Due to the high number and severity of these side effects, the World Health Organization stopped the study.Despite these study conclusionshttpsctiexchange.orgmale-hormonal-contraception-informed-step-forward, it is very important to note that more than 75 of study participants reported being willing or more than willing to use this method of contraception. Only 5 of the men who participated said they would not use the method of contraception again.If a hormonal approach is not feasible in the near-term, could a non-hormonal, long-acting, reversible contraceptive for men become a game-changer At Contraline, we are developing a vas-occlusive contraceptive device that is long-lasting, non-hormonal, and reversible. The procedure involves a quick and minimally invasive procedure known as Vasintomy, whereby a gel is implanted into the vas deferens to block sperm flow from the epididymis into the ejaculate.The holy grail for a long-term male contraceptive is reversibility. Reversibility would allow the potential market to expand from just men who are family-complete to those who are sexually active. Today, vasectomy reversals take three hours, require general anesthesia, and cost up to 15,000. Not surprisingly, only 6 of men who receive a vasectomy ever get the reversal. Vas-occlusive gels are on the horizon because reversing a gel seems easier than stitching back together a ligated vas and would come with fewer side effectshttppmj.bmj.comcontent77912656.Published data on mens acceptability of vas-occlusive contraceptives are still lacking. A recently published modeling paperhttpac.els-cdn.comS00107824173043041-s2.0-S0010782417304304-main.pdftid37810c44-9898-11e7-8f8f-00000aacb362acdnat150531669979f17effae04a8c151086063c9fbaa12 assumed a conservative acceptability rate of 10 among users who would switch from existing methods as well as brand new contraceptive users. Contraline routinely receives inquiries from men asking to participate in clinical trials. There is definitely potential user interest in a vas-occlusive device.The final piece of the puzzle will be to get provider buy-inif you make it, will physicians support its use In my discussions with numerous urologists, I have found that most are cautiously excited about the potential for a vas-occlusive contraceptive. Many of them see first-hand the interest by their patients for a long-acting, reversible option. Demonstrating that the contraceptive is safe and highly effective, and that the procedure can be performed reliably will be key to getting urologist buy-in.All in all, a long-acting, reversible contraceptive for men would truly be revolutionary. It would alleviate the pressure placed currently on women, the majority users of contraceptives. Even given the conservative modeling estimate of 10 acceptability, a new male contraceptive could decrease the number of unintended pregnancies around the world on the order of hundreds of thousands, potentially millions.Who knows Maybe a vas-occlusive device will create as much buzz as the Tesla Model 3 among men seeking to control their fertility. Aside from excitement, it surely would create a new realm of shared responsibility between partners, and could become a societal game-changer. Heres to having a new, long-acting male contraceptive in the market by 2021.

April 13, 2017

Contraline Secures $2.25 millionin Seed Financing

CHARLOTTESVILLE, Virginia Contraline, a biotechnology company developing a novel male contraceptive, announced it has raised 2.25 million in Seed funding. The round was led by San Francisco-based venture capital firm, Founders Fund, with investments also coming from Center for Innovative Technology, Abstract Ventures, Afton Scientific, and angel investors including Jaffray Woodriff and Jason Calacanis.Co-Founder and CEO Kevin Eisenfrats stated, Were thrilled to bring in a group of new and existing investors who believe in our vision of commercializing the first long-lasting, reversible male contraceptive. Many of these investors have followed our work and have seen how much progress weve made in a relatively short period of time.Contraline plans on using these funds to continue the research and development of its male contraceptive product, Adam, a polymer gel that is implanted into the vas deferens to block sperm flow. The Company also plans to initiate pre-clinical trials for Adam later this year. Overall, our goal is to deliver a new male contraceptive product to market by 2021 with the goal of replacing the vasectomy market by 2026, says Eisenfrats.In addition to being reversible, Contralines procedure Vasintomy is intended to be non-surgical. Rather than making an incision and exteriorizing the vas deferens like in vasectomy, urologists use an ultrasound to guide the injection through the skin. Therefore, no incisions, scalpels, or sutures are required. The procedure is anticipated to be 3-4 times faster and have less complications than vasectomy.Contraline recently moved into its new headquarters, ContraLab, a 2,200 sq. ft. lab and office space in Charlottesville, VA. The company plans on using this space for all polymer synthesis and characterization work, with animal studies taking place at various universities and contract research organizations that Contraline partners with.The Company has raised a total of 3.1 million to date including a previous round of funding from angel investors, grants, and multiple university and national awards.More information about the fundraise can be found on TechCrunchhttpstechcrunch.com20170405meet-the-company-thats-looking-to-make-non-surgical-male-birth-control-a-reality.

May 07, 2021

Contraline ExpandsBoard of Directors

Medical Device Industry Veteran, Martin J. Emerson, Joins Contraline Board New Board appointment strengthens Contraline with world-class expertise in urology device development, approvals, commercial strategy, and business developmentCharlottesville, VA Contraline, Inc., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has appointed medical device industry executive Martin Emerson to its Board of Directors.Marty joins our Board at an exciting time as we transition to a clinical-stage organization and plan to initiate our first-in-human clinical trial of ADAM, the worlds first injectable hydrogel designed to provide long-lasting, non-permanent vas-occlusion for men, says Kevin Eisenfrats, Co-Founder and Chief Executive Officer of Contraline. We are charting the path to bring a revolutionary reproductive health product like ADAM to market, and we will greatly benefit from Martys wealth of knowledge and successful experience leading numerous companies with innovative medical devices, including in urology.Mr. Emerson brings to Contraline over 30 years of medical device industry experience. From 2005-2008, he served as the CEO of American Medical Systems AMS, a publicly-traded urology and gynecology device company with sales of over 500 million later acquired by Boston Scientific for 1.6 billion. After AMS, Mr. Emerson served as the president and CEO of Galil Medical, a cryoablation device company acquired for 110M by BTG plc, and currently serves as the president and CEO of Monteris Medical. He has also held various management positions, both domestic and international, with Boston Scientific Corporation and Baxter International. Mr. Emerson currently serves on the Board of Directors for SubioMed and Tepha Medical Devices, and has previously served on other boards of both public and private medical device companies. He holds a Bachelor of Science in Accounting from Marquette University.Contraline is pioneering a new modality for men to control their fertility in a non-hormonal way and that could transform family planning around the globe, said Mr. Emerson. I look forward to working with the team to help guide the strategy of accelerating a robust clinical program to validate their innovative hydrogel technology and bringing ADAM to multiple markets to have significant impact on men, families, and society as a whole. In addition to CEO Kevin Eisenfrats and Martin Emerson, Contralines Board of Directors includes-Michael King, PhD, chemical engineering professor with more than 30 years experience in research and manufacturing related to the commercialization of new pharmaceuticals and vaccines as SVP of Science and Technology at Merck and as a consultant to the Bill Melinda Gates Foundation.-Tom Thorpe, MBA, CEO of Afton Scientific, a cGMP contract manufacturer of sterile drugs and products for use in new drug development and production.-Gurdane Bhutani, founder and managing partner at MBX Capital, an early-stage healthcare venture fund.

November 18, 2020

Male Contraceptive Initiative Invests $1 Millionin Contraline to Conduct Clinical Trial on ADAM™

Durham, NC and Charlottesville, VA Male Contraceptive Initiative MCI, a 501c3 non-profit, has partnered with the medical device company Contraline, Inc. to provide a 1 million Program Related Investment PRI to support a first-in-human clinical trial for the companys novel vas-occlusive contraceptive device, ADAM. This is the first PRI from Male Contraceptive Initiative and is representative of the organizations continued evolution. We are very excited about adding program related investments to our portfolio as a means of accelerating male contraceptive product development through a team science approach. Returns on these investments will go directly back into supporting research efforts to continue driving the field of non-hormonal male contraception forward, said MCI Executive Director Heather Vahdat. Contraline is a particularly exciting investment opportunity as they are the first US-based company to bring a novel non-hormonal male contraceptive to the clinical stage it shows that we are moving closer and closer to realizing a more robust portfolio of contraceptive options that includes more methods for men, Ms. Vahdat added. Contraline has developed ADAM, the worlds first injectable hydrogel designed to provide long-lasting barrier contraception for men. ADAM is designed to be inserted into the vas deferens through a quick and minimally invasive outpatient procedure using local anesthesia, where the hydrogel blocks the flow of sperm without affecting sensation or ejaculation. ADAM may be the first set-and-forget male contraceptive method, similar to intrauterine devices IUDs for women. MCIs investment in Contraline will be used to establish proof-of-concept of safety and feasibility of the ADAM device and procedure through a human clinical trial. This is an important first step prior to conducting a larger efficacy study required for gaining regulatory approval and widespread consumer access to the procedure. We have been excited about Contralines technology since 2018, when we provided them with a grant to validate their benchtop and preclinical studies. Given the success of their science to date, we are pleased to expand our collaboration as Contraline continues advancing their male contraceptive towards the clinic, said MCI Research Director Dr. Logan Nickels. We are grateful to MCI for their dedication to supporting innovation in male contraception and for recognizing the transformative potential of ADAM, said Kevin Eisenfrats, Contraline co-founder and chief executive officer. At Contraline, we are dedicated to developing new options for men who desire to take control of their fertility and we look forward to having our lead product, ADAM, enter the clinic soon. With over 5 million invested in product development, MCI seeks to advance male contraceptive research projects to market in order to achieve its organizational vision of Reproductive Autonomy for All. MCIs mission is, To empower men, and couples, to fully contribute to family planning goals by providing them the resources they need for reproductive autonomy. -------------------------------------------------- About Male Contraceptive Initiative Male Contraceptive Initiatives vision is Reproduction Autonomy for All, and works to accomplish this by bringing new male contraceptives to market. The non-profit accomplishes this through direct funding, technical support, research, and advocacy. They believe that couples deserve options and that they offer the biggest potential impact by focusing on male contraceptives. Its time men are given more opportunities to contribute toward family planning. About Contraline Contraline is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception. The company is developing ADAMTM, a non-hormonal male contraceptive that uses proprietary advancements in hydrogel technology for occlusion of the vas deferens. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia. To learn more, visit httpwww.contraline.com.

October 26, 2020

Virginia Catalyst Awards Contraline$600,000 for Clinical Translation

RICHMOND, VA October 26, 2020 The Virginia Catalyst, formerly known as the Virginia Biosciences Health Research Corporation VBHRC, today announced that it has awarded 2.1 million in grants to three life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded as Round 11 of Virginia Catalysts ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet needs for improving human health, and that can create high-paying jobs in the Commonwealth. The life sciences industry has been a catalyst for economic growth during the pandemic and is poised to accelerate Virginias recovery in a post COVID world, said Mike Grisham, CEO, Virginia Catalyst.Through programs like these grant initiatives, Virginia Catalyst and the Commonwealth of Virginia are investing in the future by driving additional capital and business opportunity through the life sciences. The funding we provide for these innovative programs helps generate significant outside capital and interest in Virginia. We are proud to announce the awardees for our eleventh round of funding as we help to finance the commercialization of Virginias innovations and investment in research infrastructure tools to facilitate bioscience research.Contraline is one of three companies to have been selected in this years round of funding. Contralines project, Clinical Translation of a Male Contraceptive Procedure will involve collaborating with UVA and VCU to prepare the companys lead product ADAM for use in humans.Nearly half of all pregnancies in the United States each year are unintended, with three-fourths of couples relying on the female partner for birth control. Currently, mens options are limited to condoms and vasectomy, creating a substantial opportunity for a novel male contraceptive to contribute to family planning and improved quality of life. Contraline, a spin-out from UVA, is a medical device company developing ADAM, the worlds first injectable hydrogel designed to provide long-lasting barrier contraception for men. The hydrogel is inserted into the vas deferens through a quick outpatient procedure, which has been shown to be safe and effective in large animal studies. The Virginia Catalyst grant will support our translational research collaborating with UVA and VCU urology departments to ready our male contraceptive ADAM for a first-in-human clinical trial in 2021. This will be the first clinical trial conducted on a non-hormonal male contraceptive device in over 20 years and we are excited to partner with Virginia Catalyst to enable it. - Kevin Eisenfrats, Co-Founder and Chief Executive Officer, Contraline, Inc.

September 30, 2020

Dr. Greg Groverto Present at Annual PODD Conference

CHARLOTTESVILLE, VA -- On October 9th, 2020, Dr. Greg Grover, Chief Technology Officer of Contraline, Inc., will present at the annual Partnership Opportunities in Drug Delivery PODD Conference. His talk titled, The Future of Male Contraception, is part of the Soapbox Sessions sponsored by Pfizer, which features presentations on cutting edge technologies and inventions. Dr. Grover will highlight Contralines key advancements in hydrogel technology as well as an update on Adam, a long-lasting and reversible contraceptive for men. For more information about the PODD Conference, please visit httpstheconferenceforum.orgconferencespartners-in-drug-deliveryoverviewhttpstheconferenceforum.orgconferencespartners-in-drug-deliveryoverview

January 24, 2019

Male Contraceptive InitiativeAwards Grant to Contraline

Charlottesville, VA Male Contraceptive Initiative MCI, a private non-profit foundation, announced the award of a 200,000 grant to the medical device company Contraline, Inc. for the development of a novel vas-occlusive contraceptive device. Contraline has invented a proprietary hydrogel that is implanted into the vas deferens through a minimally invasive, outpatient procedure. The hydrogel works by blocking sperm from traveling through the vas deferens. Similar to intrauterine devices IUDs for women, Contralines contraceptive is designed to last for years and be reversible. MCIs funding will be used by Contraline to refine the implantation procedure in preparation for filing with the FDA and initiating clinical trials.Vas-occlusion is a promising non-hormonal male contraceptive approach that has been attempted for decades, yet no product has been realized. Contraline has taken a new multidisciplinary approach towards solving this problem. Our team has developed a vas-occlusive hydrogel that is easily injectable, safe, and long-lasting. The key innovation is that we designed the hydrogel specifically for the vas environment and the occlusion of sperm. We are constantly improving the product and procedure with a focus on clinical translation and patient satisfaction, said Kevin Eisenfrats, Co-Founder and CEO of Contraline. We are honored that MCI has chosen to partner with Contraline to bring the first long-lasting, non-hormonal, and reversible male contraceptive to market.Bringing a non-hormonal, reversible method of male contraception to market is MCIs mission and were extremely excited about the work that Contraline is doing in the vas-occlusive space, adds MCI Executive Director Heather Vahdat. We believe that these methods have the potential to change the contraceptive landscape and we look forward to collaborating with the Contraline team in making this a reality.

April 22, 2018

Contraline CEO, Kevin Eisenfrats, to Present at the 43rd American Society of Andrology Conference

April 22, 2018 Charlottesville, Virginia Kevin Eisenfrats, Co-Founder and CEO of Contraline, Inc., will be sharing the history, current-state-of-the-art, and innovation in vas-occlusive medical devices in a featured talk at the American Society of Andrology 43rd Annual Conference in Portland, Oregon. His talk, titled The Past, Present, and Future of Vas-Occlusive Medical Devices, will be part of the symposium on male contraception on April 24th. The commercialization potential of methods to occlude the vas deferens have promise to be the first long-lasting, non-hormonal, and reversible male contraceptive approach. With about half of all pregnancies unplanned, and the burden of birth control mostly shouldered by women, there is a huge need for effective male contraception, said Kevin Eisenfrats. Contraline is dedicated to developing a long-acting, reversible contraceptive LARC for men and we are honored to be included among other leading researchers pursuing male contraceptive approaches.Other speakers in the symposium include Dr. Daniel Johnston, Chief of the NIH Contraception Research Branch Dr. Stephanie Page from the University of Washington and Dr. Michael ORand from the University of North Carolina. The symposium will highlight funding available for male contraceptive research, as well as provide updates on various hormonal and non-hormonal male contraceptive drugs in development. About ContralineContraline is a medical device company developing novel hydrogels for reproductive and contraceptive applications. The Company is focused on providing couples with new options for male contraception with a long-acting, non-hormonal, and reversible device. Contralines first product in development is Adam, which applies cutting-edge hydrogel technology to physically block sperm within the male reproductive tract.

September 27, 2017

Acceptability of a Long-LastingReversible Male Contraceptive

This article, written by Contralines CEO Kevin Eisenfrats, was originally postedhttpsctiexchange.orgfinding-acceptable-long-acting-reversible-male-contraceptive to FHI360s Contraceptive Technology Innovation CTI Exchange as part of their guest-author blog series. Almost every month or so, an article is published that reads New male contraceptive is on the horizon MIT Tech Reviewhttpswww.technologyreview.coms608333the-tech-world-is-convinced-2021-is-going-to-be-the-best-year-ever has even gone so far as to say that male birth control might be one of the most interesting technologies to be released in 2021, alongside electric vehicles, virtual reality, and lab-grown chickens. Judging by the headlines, youd think that men are as excited to try a male contraceptive as they are to drive the Tesla Model 3.Are they excited We know for sure that men are NOT excited about existing methods. Condoms have a dissatisfaction rate of 57 and the number of vasectomies performed in the U.S. has stagnated at 500,000 per year. We also know that men ARE interested in controlling their fertility over the long-term. In a 2005 studyhttpsacademic.oup.comhumreparticle202549603220 of 9,000 men across nine countries, 55 of the respondents reported being willing or very willing to use a new method of male contraception. That ranged from 28.5 in Indonesia to 71.4 in Spain. The most appealing frequency for taking the contraceptive Once per year so it seems interest among men in a long-acting contraceptive option is real.The next question then is whether a hormonal method would be acceptable. In a recent clinical trialhttpsacademic.oup.comjcemarticle-lookupdoi10.1210jc.2016-2141 sponsored by the World Health Organization, men were injected with a hormonal contraceptive under development that would provide contraception for up to a year. The study regimen was not easy each man received an injection of a testosterone and progestin derivative into his gluteus every eight weeks, and was required to come back for semen analysis and physical check-ups every two weeks. The contraceptive was found to be 96 effective a very good rating, but not as effective as vasectomy, the Pill, IUDs, or implants. However, a high number of adverse effects 1,491 to be exact, including acne, increased libido, depression, and mood disorders, were noted. Due to the high number and severity of these side effects, the World Health Organization stopped the study.Despite these study conclusionshttpsctiexchange.orgmale-hormonal-contraception-informed-step-forward, it is very important to note that more than 75 of study participants reported being willing or more than willing to use this method of contraception. Only 5 of the men who participated said they would not use the method of contraception again.If a hormonal approach is not feasible in the near-term, could a non-hormonal, long-acting, reversible contraceptive for men become a game-changer At Contraline, we are developing a vas-occlusive contraceptive device that is long-lasting, non-hormonal, and reversible. The procedure involves a quick and minimally invasive procedure known as Vasintomy, whereby a gel is implanted into the vas deferens to block sperm flow from the epididymis into the ejaculate.The holy grail for a long-term male contraceptive is reversibility. Reversibility would allow the potential market to expand from just men who are family-complete to those who are sexually active. Today, vasectomy reversals take three hours, require general anesthesia, and cost up to 15,000. Not surprisingly, only 6 of men who receive a vasectomy ever get the reversal. Vas-occlusive gels are on the horizon because reversing a gel seems easier than stitching back together a ligated vas and would come with fewer side effectshttppmj.bmj.comcontent77912656.Published data on mens acceptability of vas-occlusive contraceptives are still lacking. A recently published modeling paperhttpac.els-cdn.comS00107824173043041-s2.0-S0010782417304304-main.pdftid37810c44-9898-11e7-8f8f-00000aacb362acdnat150531669979f17effae04a8c151086063c9fbaa12 assumed a conservative acceptability rate of 10 among users who would switch from existing methods as well as brand new contraceptive users. Contraline routinely receives inquiries from men asking to participate in clinical trials. There is definitely potential user interest in a vas-occlusive device.The final piece of the puzzle will be to get provider buy-inif you make it, will physicians support its use In my discussions with numerous urologists, I have found that most are cautiously excited about the potential for a vas-occlusive contraceptive. Many of them see first-hand the interest by their patients for a long-acting, reversible option. Demonstrating that the contraceptive is safe and highly effective, and that the procedure can be performed reliably will be key to getting urologist buy-in.All in all, a long-acting, reversible contraceptive for men would truly be revolutionary. It would alleviate the pressure placed currently on women, the majority users of contraceptives. Even given the conservative modeling estimate of 10 acceptability, a new male contraceptive could decrease the number of unintended pregnancies around the world on the order of hundreds of thousands, potentially millions.Who knows Maybe a vas-occlusive device will create as much buzz as the Tesla Model 3 among men seeking to control their fertility. Aside from excitement, it surely would create a new realm of shared responsibility between partners, and could become a societal game-changer. Heres to having a new, long-acting male contraceptive in the market by 2021.

April 13, 2017

Contraline Secures $2.25 millionin Seed Financing

CHARLOTTESVILLE, Virginia Contraline, a biotechnology company developing a novel male contraceptive, announced it has raised 2.25 million in Seed funding. The round was led by San Francisco-based venture capital firm, Founders Fund, with investments also coming from Center for Innovative Technology, Abstract Ventures, Afton Scientific, and angel investors including Jaffray Woodriff and Jason Calacanis.Co-Founder and CEO Kevin Eisenfrats stated, Were thrilled to bring in a group of new and existing investors who believe in our vision of commercializing the first long-lasting, reversible male contraceptive. Many of these investors have followed our work and have seen how much progress weve made in a relatively short period of time.Contraline plans on using these funds to continue the research and development of its male contraceptive product, Adam, a polymer gel that is implanted into the vas deferens to block sperm flow. The Company also plans to initiate pre-clinical trials for Adam later this year. Overall, our goal is to deliver a new male contraceptive product to market by 2021 with the goal of replacing the vasectomy market by 2026, says Eisenfrats.In addition to being reversible, Contralines procedure Vasintomy is intended to be non-surgical. Rather than making an incision and exteriorizing the vas deferens like in vasectomy, urologists use an ultrasound to guide the injection through the skin. Therefore, no incisions, scalpels, or sutures are required. The procedure is anticipated to be 3-4 times faster and have less complications than vasectomy.Contraline recently moved into its new headquarters, ContraLab, a 2,200 sq. ft. lab and office space in Charlottesville, VA. The company plans on using this space for all polymer synthesis and characterization work, with animal studies taking place at various universities and contract research organizations that Contraline partners with.The Company has raised a total of 3.1 million to date including a previous round of funding from angel investors, grants, and multiple university and national awards.More information about the fundraise can be found on TechCrunchhttpstechcrunch.com20170405meet-the-company-thats-looking-to-make-non-surgical-male-birth-control-a-reality.

1216 Harris Street, Charlottesville, VA 22903
© 2020 Contraline, Inc. All Rights Reserved.
Privacy policy